JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

BACKGROUND: Poly(ADP‐ribose) polymerase (PARP) inhibitors may synergize with programmed cell death receptor‐1 (PD‐1) inhibitors to enhance adaptive and innate antitumor immune responses. In the phase 2 JASPER study (NCT04475939), the PARP inhibitor niraparib was evaluated in combination with the PD‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramalingam, Suresh S., Thara, Eddie, Awad, Mark M., Dowlati, Afshin, Haque, Basir, Stinchcombe, Thomas E., Dy, Grace K., Spigel, David R., Lu, Sharon, Iyer Singh, Nithya, Tang, Yongqiang, Teslenko, Iryna, Iannotti, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293160/
https://www.ncbi.nlm.nih.gov/pubmed/34478166
http://dx.doi.org/10.1002/cncr.33885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293160/
https://www.ncbi.nlm.nih.gov/pubmed/34478166
http://dx.doi.org/10.1002/cncr.33885

Ejemplares similares